Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about DexCom, Inc.
DexCom, Inc. News
DexCom, Inc. Quantitative Score
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DexCom, Inc. Earnings & Revenue
DexCom, Inc. Financials
Table Compare
Compare DXCM metrics with: | |||
|---|---|---|---|
Earnings & Growth | DXCM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | DXCM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | DXCM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | DXCM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
DexCom, Inc. Income
DexCom, Inc. Balance Sheet
DexCom, Inc. Cash Flow
DexCom, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
DexCom, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
DexCom, Inc. Executives
| Name | Role |
|---|---|
| Mr. Kevin Ronald Sayer | Executive Chairman, Chief Executive Officer & President |
| Mr. Donald M. Abbey | Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs |
| Mr. Jacob Steven Leach | Executive Vice President & Chief Operating Officer |
| Mr. Jereme M. Sylvain CPA | Executive Vice President, Chief Financial Officer & Chief Accounting Officer |
| Mr. Michael Jon Brown | Executive Vice President & Chief Legal Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Kevin Ronald Sayer | Executive Chairman, Chief Executive Officer & President | Male | 1958 | 1.29M |
| Mr. Donald M. Abbey | Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs | Male | 1967 | 766.8K |
| Mr. Jacob Steven Leach | Executive Vice President & Chief Operating Officer | Male | 1978 | 693.11K |
| Mr. Jereme M. Sylvain CPA | Executive Vice President, Chief Financial Officer & Chief Accounting Officer | Male | 1980 | 621.95K |
| Mr. Michael Jon Brown | Executive Vice President & Chief Legal Officer | Male | 1971 | 607.24K |
DexCom, Inc. Insider Trades
| Date | 8 May |
| Name | Driscoll Rimma |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5074 |
| Date | 8 May |
| Name | GALA RENEE D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5074 |
| Date | 8 May |
| Name | Malady Kyle |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5192 |
| Date | 8 May |
| Name | Dahut Karen M |
| Role | Director |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 2613 |
| Date | 8 May |
| Name | Dahut Karen M |
| Role | Director |
| Transaction | Acquired |
| Type | G-Gift |
| Shares | 2613 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 8 May | Driscoll Rimma | Director | Acquired | A-Award | 5074 |
| 8 May | GALA RENEE D | Director | Acquired | A-Award | 5074 |
| 8 May | Malady Kyle | Director | Acquired | A-Award | 5192 |
| 8 May | Dahut Karen M | Director | Disposed | G-Gift | 2613 |
| 8 May | Dahut Karen M | Director | Acquired | G-Gift | 2613 |